Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + gemcitabine
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intraperitoneal
01
Overview
Nab-paclitaxel + gemcitabine is an investigational combination chemotherapy regimen currently being evaluated for the treatment of peritoneal metastases from pancreatic cancer. The regimen consists of nab-paclitaxel, a nanoparticle albumin-bound formulation of the taxane paclitaxel that stabilizes microtubules to inhibit mitosis, and gemcitabine, a pyrimidine nucleoside analog that inhibits DNA synthesis and ribonucleoside reductase. In the context of the Nab-PIPAC Phase II trial (NCT05371223), nab-paclitaxel is administered both intravenously and via Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC), a laparoscopic delivery method designed to enhance drug penetration into peritoneal nodules, while gemcitabine is administered intravenously. This combination approach aims to address the poor prognosis and limited treatment options for patients with advanced pancreatic cancer involving the peritoneum.
- Brand names
- Gemzar
- Other names
- nab-paclitaxel plus gemcitabinenab-paclitaxel/gemcitabine
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + gemcitabine.